EXHIBIT 10.27
BIOMARIN PHARMACEUTICAL INC.
CONVERTIBLE NOTE PURCHASE AGREEMENT
This Convertible Note Purchase Agreement (the "AGREEMENT") is made as of
April 12, 1999, by and between BioMarin Pharmaceutical Inc., a Delaware
corporation (the "COMPANY"), and the individuals listed on the Schedule of
Purchasers attached hereto as Exhibit A (the "PURCHASERS").
---------
1. PURCHASE AND SALE OF NOTE. In consideration of ________ dollars
-------------------------
($_____), the receipt of which is hereby acknowledged by the Company, and
subject to the terms and conditions of this Agreement, the Company hereby agrees
to sell to Purchasers and Purchasers hereby agree to purchase from the Company,
Convertible Promissory Notes, in the form attached hereto as Exhibit B (the
---------
"NOTES"), in the principal amounts set forth opposite each Purchaser's name on
Exhibit A.
---------
2. REGISTRATION RIGHTS. Purchasers shall become parties to the Amended
-------------------
and Restated Registration Rights Agreement between the Company and certain
holders of the Company's Common Stock, a copy of which is attached hereto as
Exhibit C. Under the terms of this Amended and Restated Registration Rights
---------
Agreement, upon conversion of the Notes into shares of the Company's Common
Stock pursuant to the terms of the Notes, the Purchasers shall be entitled to
certain registration rights and shall be subject to certain other restrictions
contained therein with regard to the shares of Common Stock issued upon
conversion of the Notes held by each Purchaser.
3. CLOSING AND DELIVERY OF NOTES. Payment for and delivery of the Notes
-----------------------------
may be completed in more than one closing, with the first such closing (each a
"CLOSING") to occur at the offices of Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx, 000 Xxxx
Xxxx Xxxx, Xxxx Xxxx, Xxxxxxxxxx at 8:00 a.m. (Pacific Daylight Time) (the
"CLOSING TIME") on such date as the Company and the Purchaser may agree (the
"CLOSING DATE"), but in any event no Closing shall be held later than JUNE 30,
1999 (unless extended by mutual agreement of the Company and the Purchaser).
The Notes will be delivered at each Closing against payment to the Company
by each Purchaser of their respective principal amount enumerated on the
Schedule of Purchasers attached hereto as Exhibit A. The principal amount shall
---------
be paid by each Purchaser by wire transfer to the following account: BIOMARIN
PHARMACEUTICAL INC., BANK OF AMERICA, 000 XXXXXXXX XXXXX, XXXXX 000, XXXXXXX, XX
00000; ACCOUNT NUMBER: 1472800983; ROUTING #000000000; CONTACT PERSON: XXXXXXX
XXXXXX, or such other means as Purchaser and the Company shall mutually agree.
Each Purchaser purchasing the Notes pursuant to the exemption from the
registration requirements of the Securities Act of 1933, as amended, contained
in Regulation S (as discussed in Section 8(i) hereto), on its own behalf or on
behalf of others for whom it is contracting hereunder, hereby appoints the
Agent, with full power of substitution, as its true and lawful attorney and
agent with the full power and authority in its place and stead to swear,
execute, file and record any document necessary to give effect to the delivery
of the Notes to the Agent, to terminate this Agreement on its behalf in the
event that any condition precedent to the Closing has not been satisfied, to
execute a receipt for the Notes, and to modify or waive any conditions or grant
any waivers on its behalf in connection with the transactions contemplated by
this Agreement, the Agency Agreement between XxXxxx Asset Management S.A. (the
"AGENT") and the Company dated
-1-
April 12, 1999 (the "AGENCY AGREEMENT") and the Amended and Restated
Registration Rights Agreement.
4. CONDITIONS TO CLOSING OF THE PURCHASER. The Purchaser's obligation to
--------------------------------------
purchase the Notes at the Closing is, at the option of the Purchaser, subject to
fulfillment on or prior to the Closing Date of the following conditions:
(a) Representations and Warranties Correct. The representations and
--------------------------------------
warranties made by the Company in Section 6 hereof shall be true and correct on
the applicable Closing Date with the same force and effect as if such
representations had been made on and as of said date.
(b) Covenants. All covenants, agreements and conditions contained in
---------
this Agreement to be performed by the Company on or prior to the applicable
Closing Date shall have been performed or complied with in all respects.
(c) Compliance Certificate. The Company shall have delivered to the
----------------------
Purchaser a certificate, executed by the President of the Company, dated as of
the applicable Closing Date, and certifying to the fulfillment of the conditions
specified in Sections 4(a) and 4(b) above.
(d) Secretary's Certificate. The Company shall have delivered to the
-----------------------
Purchaser a certificate, executed by the Secretary of the Company, dated as of
the applicable Closing Date, and certifying as to the authenticity of the
Amended and Restated Certificate of Incorporation and the Bylaws, the
resolutions of the Board authorizing the transactions contemplated hereby and
the incumbency of the Company's officers.
(e) Opinion of Counsel. Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx, counsel to
------------------
the Company, shall have delivered to the Purchaser an opinion, in form and
substance reasonably satisfactory to Purchaser, in the form attached hereto as
Exhibit D.
---------
(f) Blue Sky. The Company shall have obtained all permits and
--------
qualifications required by any state in connection with the offer and sale of
the Notes and the shares of Common Stock issuable upon conversion thereof, or
secured an exemption therefrom.
(g) Convertible Note Purchase Agreement. The Company shall have
-----------------------------------
executed and delivered to the Purchaser a copy of this Agreement.
(h) Waiver of Pre-emptive Rights. The Company shall have received
----------------------------
written waivers of the rights triggered by the offer and sale of the Notes and
the shares of Common Stock issuable upon conversion thereof under: (i) the
letter to Glyko BioMedical Ltd. dated June 27, 1997, regarding certain pre-
emptive rights (the "GLYKO PRE-EMPTIVE RIGHTS LETTER"), (ii) the letter to
Genzyme Corporation dated September 4, 1998 regarding certain pre-emptive rights
(the "GENZYME PRE-EMPTIVE RIGHTS LETTER"), and (iii) the letter to BB
BioVentures L.P., dated December 30, 1997, regarding certain pre-emptive rights
(the "BB BIOVENTURES PRE-EMPTIVE RIGHTS LETTER").
5. CONDITIONS TO CLOSING OF THE COMPANY. The Company's obligation to
------------------------------------
issue and sell the Notes at the Closing to the Purchaser is, at the option of
the Company, subject to the fulfillment of the following conditions:
-2-
(a) Representations and Warranties. The representations and
------------------------------
warranties made by the Purchaser in Section 8 hereof shall be true and correct
when made, and shall be true and correct on the applicable Closing Date with the
same force and effect as if such representations had been made on and as of said
date.
(b) Blue Sky. The Company shall have obtained all permits and
--------
qualifications required by any state in connection with the offer and sale of
the Notes and the shares of Common Stock issuable upon conversion thereof, or
secured an exemption therefrom.
(c) Registration Rights Agreement. The Purchaser shall have executed
-----------------------------
and delivered to the Company the Amended and Restated Registration Rights
Agreement.
(d) Convertible Note Purchase Agreement. The Purchaser shall have
-----------------------------------
executed and delivered to the Company a copy of this Agreement.
(e) Payment. The Company shall have received from or on behalf of the
-------
Purchaser written confirmation by facsimile transmission that instructions have
been given to initiate a wire to the Company's account specified in Section 3
hereof of payment in full for the principal amount set forth opposite such
Purchaser's name on the Schedule of Purchasers attached hereto as Exhibit A.
---------
(f) Waiver of Pre-emptive Rights. The Company shall have received
----------------------------
written waivers of the rights triggered by the offer and sale of the Notes and
the shares of Common Stock issuable upon conversion thereof under the Glyko Pre-
emptive Rights Letter, the Genzyme Pre-emptive Rights Letter and the BB
BioVentures Pre-emptive Rights Letter by the respective parties thereto.
6. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby
---------------------------------------------
represents and warrants to the Purchaser that, except as otherwise set forth on
the Schedule of Exceptions attached hereto as Exhibit E, with specific reference
---------
to the subsection of this Section 6 so affected, the following will be true and
correct as of the applicable Closing Date:
(a) Organization and Standing. The Company is a Company duly
-------------------------
organized and validly existing under, and by virtue of, the laws of the State of
Delaware and is in good standing under such laws. The Company has the requisite
corporate power to own and operate its properties and assets and to carry on its
business as presently conducted. The Company is qualified to do business as a
foreign Company in the State of California.
(b) Corporate Power. The Company has all requisite legal and
---------------
corporate power to execute and deliver this Agreement, the Notes, to issue the
shares of Common Stock issuable upon conversion of the Notes and to carry out
and perform its obligations under the terms of this Agreement, the Notes and the
Amended and Restated Registration Rights Agreement.
(c) Subsidiaries. The Company has no subsidiaries or affiliated
------------
companies other than: (i) Glyko, Inc., (ii) BioMarin Genetics, Inc., and (iii)
BioMarin/Genzyme LLC. Glyko, Inc. is duly organized and validly existing under
the laws of the State of Delaware. Glyko, Inc. has the requisite corporate power
to own and operate its property and assets and to carry on its business as
presently conducted. BioMarin/Genzyme LLC is duly organized and validly existing
under and by virtue of the laws of the State of Delaware and is in good standing
under such laws. BioMarin/Genzyme LLC has the requisite power to own and operate
its property and assets and to carry on its business as
-3-
presently conducted. BioMarin Genetics, Inc. is duly organized and validly
existing under, and by virtue of the laws of the State of Delaware and is in
good standing under such laws. BioMarin Genetics, Inc. has the requisite
corporate power to own and operate its property and assets and to carry on its
business as presently conducted. Immediately prior to the Closing, Glyko
BioMedical Ltd. owns 10,925,706 shares of the Company's Common Stock.
(d) Capitalization. The authorized capital stock of the Company
--------------
consists of 50,000,000 shares of Common Stock, of which, at the date hereof,
26,176,180 shares are issued and outstanding. All issued and outstanding shares
of Common Stock have been duly authorized and validly issued, and are fully paid
and non-assessable. The Common Stock has the voting power, designations,
preferences, rights and qualifications set forth in the Amended and Restated
Certificate of Incorporation. Except as contemplated herein and except for: (i)
the pre-emptive rights granted to BB BioVentures L.P. pursuant to BB BioVentures
Pre-emptive Rights Letter, (ii) the pre-emptive rights granted to Glyko
BioMedical Ltd. pursuant to the Glyko Pre-emptive Rights Letter, (iii) the pre-
emptive rights granted to Genzyme Corporation pursuant to the Genzyme Pre-
emptive Rights Letter, (iv) options to purchase 3,406,254 shares of Common Stock
of the Company granted under its 1997 Stock Plan, as amended, and the 1998
Directors Plan, (v) warrants to purchase a total of up to 801,500 shares of
Common Stock, (vi) Genzyme Corporation's obligation to purchase up to $10
million worth of Common Stock of the Company in a private placement simultaneous
with an initial public offering of the Company's Common Stock (subject to
certain qualifications) and (vii) the obligation to issue up to 255,222 shares
of BioMarin Common Stock to employees of Glyko, Inc. upon exercise of certain of
their outstanding options to purchase capital stock of Glyko BioMedical Ltd.,
which options were assumed by the Company in connection with the acquisition of
Glyko, Inc. in October 1998, there are no options, warrants, conversion
privileges or other rights presently outstanding to purchase or otherwise
acquire any authorized but unissued shares of the capital stock or other
securities of the Company, nor any agreements or understandings with respect
thereto. The Company has reserved 2,600,000 shares of its Common Stock for
issuance upon conversion of the Notes.
(e) Financial Statements. As of the Closing Date, the Company will
--------------------
have delivered to the Purchaser the unaudited financial statements of the
Company as at December 31, 1998 (the "FINANCIAL STATEMENTS"). The Financial
Statements are complete and correct in all material respects, have been prepared
in accordance with generally accepted accounting principles (except that they do
not contain footnotes) consistently applied throughout the periods covered
thereby, and present fairly the financial position of the Company as of their
respective dates, subject to final year-end adjustments. Other than as described
in the Financial Statements, the Company has no material liabilities and knows
of no material contingent liabilities not disclosed in the Financial Statements,
except current liabilities incurred in the ordinary course of business which are
not, individually or in the aggregate, materially adverse. Within approximately
10 business days following the Closing, the Company will deliver to Purchaser
audited Financial Statements for the year ended December 31, 1998.
-4-
(f) Subsequent Events. Since December 31, 1998, there has not been:
-----------------
(i) a declaration, setting aside or payment of any dividend or other
distribution with respect to, or any direct or indirect redemption or
acquisition of, any shares of the capital stock of the Company or any of its
subsidiaries; (ii) a waiver of any material right of the Company or any of its
subsidiaries or cancellation of any material debt or claim held by the Company
or any of its subsidiaries; (iii) a loan by the Company or any of its
subsidiaries to any officer, director, employee or stockholder of the Company,
or any agreement or commitment therefor; (iv) a material loss, destruction or
damage to any property of the Company or any of its subsidiaries, whether or not
insured; (v) a labor dispute involving the Company or any of its subsidiaries or
a material change in the personnel of the Company or any of its subsidiaries or
the terms and conditions of their employment; (vi) an acquisition or disposition
of any assets (or any contract or arrangement therefor), or any transaction by
the Company or any of its subsidiaries otherwise than for fair value in the
ordinary course of business; (vii) any sale, assignment or transfer of any
patents, trademarks, copyrights, trade secrets or other intangible assets of the
Company or any of its subsidiaries or (viii) any change in any material
agreement to which the Company or any of its subsidiaries is a party or by which
any of them is bound or any other event or condition of any character that,
either individually or in the aggregate, is reasonably likely to have a material
adverse effect on the business, assets, condition (financial or otherwise) or
results of operations of the Company and its subsidiaries taken as a whole (a
"MATERIAL ADVERSE EFFECT").
(g) Authorization. All corporate action on the part of the Company,
-------------
its directors and stockholders necessary for the authorization, execution,
delivery and performance of this Agreement, the Amended and Restated
Registration Rights Agreement, the authorization, sale, issuance and delivery of
the Notes and the reservation of the shares of Common Stock issuable upon
exercise of the Notes and the performance of the Company's obligations hereunder
and thereunder has been taken or will be taken prior to the Closing. This
Agreement, the Registration Rights Agreement and the Notes, when fully executed
and delivered by the Company, shall constitute valid and binding obligations of
the Company, enforceable in accordance with their respective terms, subject to
laws of general application relating to bankruptcy, insolvency and the relief of
debtors and rules of law governing specific performance, injunctive relief or
other equitable remedies. The shares of Common Stock issuable upon conversion of
the Notes, when issued in compliance with the provisions of this Agreement and
the Notes, will be validly issued, fully paid and non-assessable, and free of
any liens or encumbrances; provided, however, that the shares of Common Stock
issuable upon conversion of the Notes may be subject to certain restrictions on
transfer under applicable state and/or United States Federal securities laws.
(h) Governmental Consents, etc. No consent, approval or authorization
--------------------------
of or designation, declaration or filing with any state or United States Federal
governmental authority on the part of the Company is required in connection with
the valid execution and delivery of this Agreement, the Amended and Restated
Registration Rights Agreement, the Notes or the issuance of the shares of Common
Stock issuable upon conversion of the Notes, or the consummation of any other
transaction contemplated hereby, except qualification (or taking such action as
may be necessary to secure an exemption from qualification, if available) under
the California Corporate Securities Law and other applicable blue sky laws, of
the offer and sale of the Notes and the shares of Common Stock issuable upon
conversion of the Notes, which filing and qualification, if required, will be
accomplished in a timely manner prior to or promptly after the Closing.
-5-
(i) Title to Properties and Assets; Liens, etc. The Company and each
------------------------------------------
of its subsidiaries has a valid leasehold interest in, or valid title to, its
properties and assets, including without limitation the assets and properties
reflected in the Company's balance sheet as of December 31, 1998, in each case
subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than:
(i) as disclosed in such balance sheet except as incurred in the ordinary course
of business since the date of such balance sheet, (ii) the lien of current taxes
not yet due and payable, and (iii) possible minor liens and encumbrances which
do not in any case materially detract from the value of the property subject
thereto or would result in a Material Adverse Effect.
(j) Litigation.
----------
(i) At the Closing Date, there are no actions, suits,
proceedings or investigations pending or threatened against the Company or any
of its subsidiaries or any their respective properties before any court or
governmental agency, nor is the Company or any of its subsidiaries subject to
any writ, injunction or order of any court or government agency (nor, to the
Company's knowledge at the date hereof, is there any basis therefor or threat
thereof) which, either individually or in the aggregate, might result in a
Material Adverse Effect, or in any material impairment of the right or ability
of the Company or any of its subsidiaries to carry on their respective
businesses as now conducted or as currently proposed to be conducted, or in any
material liability on the part of the Company or any of its subsidiaries, and,
to the Company's knowledge at the date hereof, no action, suit, proceeding or
investigation pending or threatened against the Company questions the validity
of this Agreement, the Amended and Restated Registration Rights Agreement, the
Notes or any action taken or to be taken in connection herewith or therewith.
(ii) The Company has no current plan to initiate any action,
writ, proceeding or investigation before any court or government agency.
(k) Registration Rights. Except as set forth in the Amended and
-------------------
Restated Registration Rights Agreement, the Company is not under any obligation
to register any of its presently outstanding securities, or any of its
securities which may hereafter be issued, under the Securities Act of 1933, as
amended (the "SECURITIES ACT").
(l) Brokers or Finders. The Company has not incurred, and will not
------------------
incur, directly or indirectly, any liability for brokerage or finders' fees or
agents' commissions or any similar charges in connection with this Agreement or
any transaction contemplated hereby, except such brokers or finders' fees owed
to Agent in connection with the transactions contemplated hereby pursuant to the
term of the Agency Agreement.
(m) No Breach. Neither the Company nor any of its subsidiaries is:
---------
(i) in breach or violation of any of the terms or provisions of, or in default
under, this Agreement or any indenture, mortgage, deed of trust, loan agreement
or other agreement (written or oral) or instrument to which it is a party or by
which it is bound or to which any of the property or assets of the Company or
any of its subsidiaries is subject, which breach or violation or the
consequences thereof would have a Material Adverse Effect; (ii) in violation of
the provisions of its Amended and Restated Certificate of Incorporation or
Bylaws or (iii) in violation of any statute or any order, rule or regulation of
any court or governmental agency or body having jurisdiction over it or any of
its
-6-
assets or properties, which violation or the consequences thereof would result
in a Material Adverse Effect.
(n) No Conflict. The offer and sale of the Notes and the issuance of
-----------
the shares of Common Stock issuable upon conversion of the Notes by the Company
and the performance and consummation of the transactions contemplated herein or
therein will not conflict with or result in (i) a breach or violation of any of
the terms or provisions of, or constitute a default under, any indenture,
mortgage, deed of trust, loan agreement or other agreement (written or oral) or
instrument to which the Company is bound or to which any of the property or
assets of the Company is subject, which breach or violation or the consequences
thereof would result in a Material Adverse Effect, (ii) any violation of the
provisions of the Amended and Restated Certificate of Incorporation or the
Bylaws of the Company or (iii) a violation of any statute or any order, rule or
regulation of any court or governmental agency or body having jurisdiction over
the Company or any of its assets or properties, which violation or the
consequences thereof would result in a Material Adverse Effect, except that the
offer and sale of the Notes and the shares of Common Stock issuable upon
conversion thereof will trigger rights under the Glyko Pre-emptive Rights
Letter, the Genzyme Pre-emptive Rights Letter and the BB BioVentures Pre-emptive
Rights Letter, each of which rights will be waived on or before the Closing
Date.
(o) Securities Act. Assuming compliance by the Agent with its
--------------
agreements set forth in the Agency Agreement, the transactions contemplated by
this Agreement shall be exempt from the registration requirements of the
Securities Act.
(p) Intellectual Property. The Company and its subsidiaries own or
---------------------
possess adequate licenses or other rights to use all patents, patent
applications, trademarks, trademark applications, service marks, service xxxx
applications, trade names, copyrights, manufacturing processes, formulae, trade
secrets, customer lists and know-how (collectively, "INTELLECTUAL PROPERTY")
necessary for the conduct of their respective businesses as presently conducted.
There are no claims pending or, to the best of the Company's knowledge as of the
date hereof, threatened, to the effect that the operations of the Company or any
of its subsidiaries infringe upon or conflict with the asserted rights of any
other person under any Intellectual Property, and, to the best of the Company's
knowledge, there is no basis for any such claim (whether or not pending or
threatened). No claim is pending or, to the best of the Company's knowledge,
threatened, to the effect that any Intellectual Property owned or licensed by
the Company or any of its subsidiaries, or which the Company or any of its
subsidiaries otherwise has the right to use, is invalid or unenforceable by the
Company or such subsidiary, and, to the best of the Company's knowledge, there
is no basis for any such claim (whether or not pending or threatened).
(q) Environmental Laws. To the best of the Company's knowledge,
------------------
neither the Company nor any of its subsidiaries is in violation of any
applicable statute, law or regulation relating to the environment or
occupational health or safety, and to the best of the Company's knowledge no
material expenditures are or will be required in order to comply with any such
existing statute, law or regulation.
(r) Confidentiality. The Company and each of its subsidiaries has
---------------
taken all reasonable measures to protect and preserve the confidentiality of all
their respective trade secrets and other non-patented proprietary information,
including without limitation the procurement of
-7-
proprietary invention assignments and non-disclosure and non-competition
agreements from employees, consultants, sub-contractors, customers and other
persons who have access to such information. To the best of the Company's
knowledge as of the date hereof, the procedures implemented by the Company and
each of its subsidiaries are in conformity with the practices of similarly
situated companies in its industry.
(s) Taxes. The Company has filed all necessary United States Federal,
-----
state, municipal, property, income and franchise tax returns and has paid all
taxes shown as due thereon or otherwise owed by it to any taxing authority and
there is no tax deficiency which has been or, to the best of the knowledge of
the Company as of the date hereof, might be asserted against the Company which
would have a Material Adverse Effect. The Company has not received notice of any
audit from any taxing authority, and no controversy with respect to taxes of any
type is pending or, to the best knowledge of the Company, threatened. The
Company has paid all applicable United States Federal and state payroll and
withholding taxes, including but not limited to FICA, FUTA, state unemployment
taxes and income taxes.
(t) Employment Matters. There is no collective bargaining or other
------------------
union agreement to which the Company or any of its subsidiaries is a party or by
which any of them is bound, or which is currently being negotiated. Neither the
Company nor any of its subsidiaries sponsors, maintains or contributes to any
pension, retirement, profit sharing, incentive compensation, bonus or other
employee benefit plan, including without limitation any employee benefit plan
covered by Title 4 of the Employee Retirement Income Security Act of 1974
("ERISA") or any "multi-employer plan" as defined in Section 4001(a)(3) of
ERISA, other than the Company's group medical, disability and life insurance
plans (which are not subject to ERISA), and a 401(k) plan to which the Company
makes no contributions. To the best knowledge of the Company at the date hereof:
(i) no employee of the Company or any of its subsidiaries is a party to or bound
by any agreement, contract or commitment, or subject to any restrictions,
particularly but without limitation in connection with any previous employment
of any such person, which might have a Material Adverse Effect, and (ii) no
officer has any present intention of terminating his employment with the Company
or any of its subsidiaries, and the Company has no present intention of
terminating any such employment.
(u) Full Disclosure. This Agreement and the exhibits hereto, the
---------------
Amended and Restated Registration Rights Agreement and the Notes do not contain
any untrue statement of a material fact nor omit to state a material fact
necessary in order to make the statements contained herein or therein, in light
of the circumstances in which they were made, not misleading. To the best
knowledge of the Company, there are no facts which (individually or in the
aggregate) material adversely affect the business, assets, liabilities,
financial conditions, prospects or operations of the Company that have not been
set forth in this Agreement and the exhibits hereto, the Amended and Restated
Registration Rights Agreement and the Notes.
-8-
7. CERTAIN MATTERS RELATING TO THE OFFER AND SALE OF THE SHARES. The
------------------------------------------------------------
Purchaser, on its own behalf or, for Purchasers acquiring Regulation S exempt
Notes (or on behalf of others for whom it is contracting hereunder) acknowledges
and agrees that: (a) it (or others for whom it is contracting hereunder) has not
been provided with a registration statement, prospectus or any similar document
in connection with its purchase of the Notes and the shares of Common Stock
issuable upon conversion of the Notes; (b) its decision to execute this
Agreement and the Amended and Restated Registration Rights Agreement and to
purchase the Notes and the shares of Common Stock issuable upon conversion of
the Notes (on its own behalf or on behalf of others for whom it is contracting
hereunder) has not been based upon any verbal or written representations as to
fact or otherwise made by or on behalf of the Agent or the Company and that its
decision (or the decision of others for whom it is contracting hereunder) is
based upon the information, representations and covenants of the Company
contained in this Agreement and publicly available information concerning the
Company (any such information having been delivered to it without independent
investigation or verification by the Agent); and (c) the Agent and its
directors, officers, employees, agents and representatives assume no
responsibility or liability of any nature whatsoever for the accuracy or
adequacy of any of the information, representations and covenants of the Company
contained in this Agreement or any such publicly available information or as to
whether all information concerning the Company required to be disclosed by it
has been generally disclosed.
8. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASER. The
----------------------------------------------------------
Purchaser hereby represents, warrants and covenants to the Company (which
representations, warranties and covenants shall survive the Closing) as of the
Closing Date as follows:
(a) Experience; Risk. The Purchaser has such knowledge and experience
----------------
in financial and business matters that it is capable of evaluating the merits
and risks of the purchase of the Notes pursuant to this Agreement and the shares
of Common Stock of the Company issuable upon conversion of the Notes and is
capable of protecting its interests in connection herewith. The Purchaser has
the ability to bear the economic risk of the investment, including complete loss
of the investment.
(b) Investment.
----------
(i) In the case of a Purchaser purchasing the Notes as a
principal, the Purchaser is acquiring the Notes and the shares of Common Stock
of the Company issuable upon conversion of the Notes for investment for its own
account, not as a nominee or agent, and not with a view to, or for, resale in
connection with any distribution thereof, and the Purchaser has no present
intention to sell, grant any participation in, or otherwise distribute the Notes
and the shares of Common Stock of the Company issuable upon conversion of the
Notes. The Purchaser understands that the Notes and the shares of Common Stock
of the Company issuable upon conversion of the Notes have not been registered
under the Securities Act and will be issued pursuant to an exemption from the
registration requirements thereof, which exemption depends upon, among other
things, the bona fide nature of the investment intent and the accuracy of such
Purchaser's representations as expressed herein.
(ii) In the case of a purchase of Notes and shares of Common
Stock issuable upon exercise of the Notes made in reliance upon Regulation S
promulgated under the Securities Act ("REGULATION S") where the Purchaser is
acting as agent for a disclosed principal, each
-9-
beneficial purchaser of the Notes and shares of Common Stock issuable upon
exercise of the Notes for whom the Purchaser is acting is purchasing as
principal for its own account and not for the benefit of any other person and
the Purchaser is an agent with due and proper authority to execute this
Agreement and all other documentation in connection with the purchase of the
Notes and shares of Common Stock issuable upon exercise of the Notes on behalf
of the beneficial purchaser, and this Agreement has been duly authorized,
executed and delivered by or on behalf of, and constitutes the legal, valid and
binding agreement of, the disclosed principal.
(iii) In the case of a purchase of Notes and shares of Common
Stock issuable upon exercise of the Notes made in reliance upon Regulation S
where the Purchaser is acting as trustee or as agent for a principal which is
undisclosed or identified by account number only, this Agreement has been duly
authorized, executed and delivered by, and constitutes a legal, valid and
binding agreement of, the undersigned acting in such capacity.
(c) Restricted Securities.
---------------------
(i) Rule 144. The Purchaser understands that the Notes and the
shares of Common Stock of the Company issuable upon conversion of the Notes are
"restricted securities" under United States Federal securities laws, as they are
unregistered and are being acquired from the Company in a transaction not
involving a public offering, and that under such laws and applicable regulations
promulgated thereunder the Notes and the shares of Common Stock of the Company
issuable upon conversion of the Notes may be resold without registration under
the Securities Act only in certain limited circumstances. The Purchaser
acknowledges that the Notes and the shares of Common Stock of the Company
issuable upon conversion of the Notes must be held indefinitely unless
subsequently registered under the Securities Act or an exemption from such
registration is available. The Purchaser is aware of the provisions of Rule 144
promulgated under the Securities Act, the provisions of which limit resale of
"restricted securities."
(ii) Regulation S. The Purchaser understand that if the Notes
and the shares of Common Stock of the Company issuable upon conversion of the
Notes are being acquired on a basis exempt from registration under Regulation S,
the Notes and the shares of Common Stock of the Company issuable upon conversion
of the Notes may only be resold in accordance with the provisions of Regulation
S, pursuant to registration under the Securities Act or pursuant to an available
exemption from registration thereunder.
(iii) Denial of Registration of Transfer. The Purchaser further
acknowledges and understand that if the Notes and the shares of Common Stock of
the Company issuable upon conversion of the Notes are being acquired in reliance
upon the exemption from registration contained in Regulation S the Company will
refuse to register any transfer of the Notes and the shares of Common Stock of
the Company issuable upon conversion of the Notes not made in accordance with
the provisions of Regulation S, pursuant to registration under the Securities
Act or pursuant to an available exemption from registration.
(d) No Public Market. The Purchaser understands that no public market
----------------
now exists for the Notes or the shares of Common Stock of the Company issuable
upon conversion of the Notes or for any other securities issued by the Company
and that the Company cannot assure the Purchaser that a public market will ever
exist for any securities issued by the Company.
-10-
(e) Authorization. The Purchaser has the full right, power and
-------------
authority to enter into and perform its obligations under this Agreement and the
Amended and Restated Registration Rights Agreement. This Agreement and the
Amended and Restated Registration Rights Agreement, when executed and delivered
by the Purchaser, will constitute valid and binding obligations of the
Purchaser, enforceable in accordance with their respective terms, subject to the
laws of general application relating to bankruptcy, insolvency and the relief of
debtors, rules of law governing specific performance, injunctive relief and
other equitable remedies.
(f) Government Consents. No consent, approval or authorization of or
-------------------
designation, declaration or filing with any state, United States Federal, or
foreign governmental authority on the part of the Purchaser is required in
connection with the valid execution and delivery of this Agreement and the
Amended and Restated Registration Rights Agreement by the Purchaser, and the
consummation by the Purchaser of the transactions contemplated hereby and
thereby.
(g) Further Limitations on Disposition. Without in any way limiting
---------------------------------
the representations set forth above, the Purchaser further agrees not to make
any offer or sale of all or any portion of the Notes or the shares of Common
Stock of the Company issuable upon conversion of the Notes within the United
States or to a U.S. resident unless and until:
(i) There is then in effect a Registration Statement under the
Securities Act covering such proposed offer or sale and such offer or sale is
made in accordance with such Registration Statement; or
(ii) The Purchaser shall have notified the Company of the
proposed offer or sale and shall have furnished the Company with a statement of
the circumstances surrounding the proposed disposition, and if reasonably
requested by the Company, such Purchaser shall have furnished the Company with
an opinion of counsel, reasonably satisfactory to the Company, that such offer
or sale is exempt from the registration requirements under the Securities Act.
(iii) Notwithstanding the provisions of paragraphs (i) and (ii)
above, no such registration statement or opinion of counsel shall be necessary
for a transfer by Purchaser to any transferees in transactions contemplated by
paragraph (ii) above, if all such transferees agree in writing to be subject to
the terms hereof to the same extent as if they were Purchasers hereunder.
(h) Legends. It is understood that each Note and each certificate
-------
representing the shares of Common Stock issued upon conversion of the Notes, and
any securities issued in respect thereof or exchange therefor shall bear legends
substantially in the following form (in addition to any legend required under
applicable state securities laws):
(i) In the case of Regulation S exempt securities,
"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE "1933 ACT")
AND MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN
THE ABSENCE OF SUCH REGISTRATION ONLY (A) TO THE CORPORATION,
(B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 903 OR
904 OF
-11-
REGULATION S UNDER THE 1933 ACT, OR (C) PURSUANT TO AN
AVAILABLE EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS,
PROVIDED IN SUCH LATTER CASE THAT THE HOLDER UPON REQUEST
PRIOR TO SUCH SALE FURNISHES TO THE CORPORATION AN OPINION
OF COUNSEL OF RECOGNIZED STANDING TO THAT EFFECT REASONABLY
SATISFACTORY TO THE CORPORATION. COPIES OF THE AGREEMENT
COVERING THE PURCHASE OF THESE SECURITIES AND RESTRICTING
THEIR TRANSFER MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST
MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE
SECRETARY OF THE CORPORATION AT THE PRINCIPAL EXECUTIVE
OFFICES OF THE CORPORATION.
THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT
TO A LOCKUP PERIOD OF 180 DAYS FOLLOWING THE EFFECTIVE DATE
OF A REGISTRATION STATEMENT OF THE COMPANY FILED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, AS SET FORTH IN AN
AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF
THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE
PRINCIPAL OFFICE OF THE CORPORATION. SUCH LOCKUP PERIOD IS
BINDING ON TRANSFEREES OF THESE SECURITIES."
(ii) Or in the case of Regulation D exempt securities:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH
A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION
THEREOF. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN
THE ABSENCE OF SUCH REGISTRATION UNLESS THE COMPANY RECEIVES
AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO IT STATING
THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION
AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. COPIES OF
THE AGREEMENTS COVERING THE PURCHASE OF THESE SECURITIES AND
RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT NO COST BY
WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS
CERTIFICATE TO THE SECRETARY OF THE COMPANY AT THE PRINCIPAL
EXECUTIVE OFFICES OF THE COMPANY.
(i) Status.
------
(i) Exemption from Registration. The Purchaser is acquiring
the Notes and the shares of Common Stock issuable upon conversion of the Notes
in reliance upon the exemption from the registration requirements under the
Securities Act contained in:
-12-
(1) Regulation S (___________); OR
[CHECK ONE]
(2) Regulation D (___________).
(ii) Non-U.S. Status. If not resident of the United States, the
Purchaser, whether acting as principal, trustee or agent, is neither a U.S.
person (as defined in Rule 902(o) of Regulation S promulgated under the
Securities Act) nor purchasing the Notes and the shares of Common Stock issuable
upon conversion of the Notes for the account of a U.S. person or for resale in
the United States, and the Purchaser confirms that the Notes and the shares of
Common Stock issuable upon conversion of the Notes have not been offered to the
Purchaser in the United States and that this Agreement has not been signed in
the United States.
(j) Accredited Investor Status. If the Purchaser is acquiring the
--------------------------
Notes and the shares of Common Stock issuable upon conversion of the Notes in
reliance upon the exemption from the registration requirements under the
Securities Act contained in Regulation D, then the Purchaser presently does, and
will as of the Closing Date, qualify as an "accredited investor" within the
meaning of Rule 501(a) promulgated under the Securities Act. Purchaser meets the
relevant criteria indicated on its completed and signed copy of the Accredited
Investor Questionnaire attached hereto as Exhibit F.
---------
(k) Brokers or Finders. The Purchaser has not incurred, and will not
------------------
incur, directly or indirectly, any liability for brokerage or finders' fees or
agents' commissions or any similar charges in connection with this Agreement or
any transactions contemplated hereby.
(l) Non-Contravention of Foreign Laws. The purchase of the Notes and
---------------------------------
the shares of Common Stock issuable upon conversion of the Notes by the
Purchaser does not contravene any of the applicable securities legislation in
the jurisdiction in which the Purchaser is resident and does not trigger (i) any
obligation to prepare and file a registration statement, prospectus or similar
document, or any other report with respect to such purchase, and (ii) any
registration or other obligation on the part of the Agent.
9. RELIANCE UPON REPRESENTATIONS, WARRANTIES AND COVENANTS. The Purchaser
-------------------------------------------------------
acknowledges that the representations and warranties and covenants contained in
this Agreement are made with the intent that they may be relied upon by the
Company to, among other things, determine its eligibility to purchase the Notes
and the shares of Common Stock issuable upon conversion of the Notes. The
Purchaser further agrees that by accepting the Notes, the Purchaser shall be
representing and warranting that the foregoing representations and warranties
are true as of the Closing with the same force and effect as if they had been
made by the Purchaser at the Closing.
10. ENTIRE AGREEMENT; AMENDMENT. This Agreement, the Exhibits hereto, and
---------------------------
the other documents delivered pursuant hereto constitute the full and entire
understanding and agreement among the parties with regard to the subjects hereof
and thereof. Neither this Agreement nor any term hereof may be amended, waived,
discharged or terminated other than by a written instrument signed by the
Purchaser and the Company.
-13-
11. LOCKUP AGREEMENT. Purchasers hereby agree that if so requested by the
----------------
Company or any representative of the underwriters (the "MANAGING UNDERWRITER")
in connection with any registration of the offering of any securities of the
Company under the Securities Act, Purchasers shall not sell or otherwise
transfer any shares of Common Stock issuable upon conversion of the Notes during
the 180-day period following the effective date of a registration statement of
the Company filed under the Securities Act (the "MARKET STANDOFF PERIOD"). The
Company may impose stop-transfer instructions with respect to securities subject
to the foregoing restrictions until the end of such Market Standoff Period.
12. MISCELLANEOUS.
-------------
(a) The parties agree to execute such further instruments and to take
such further action as may reasonably be necessary to carry out the intent of
this Agreement.
(b) This Agreement shall inure to the benefit of the successors and
assigns of the Company and, subject to the restrictions on transfer herein set
forth, be binding upon Purchasers, their heirs, executors, administrators,
successors and assigns.
(c) A waiver by either party of any of the terms and conditions of
this Agreement in any instance shall not be deemed or construed to be a waiver
of such terms or conditions for the future, or of any subsequent breach thereof.
(d) Any and all notices required or permitted to be given hereunder
shall be in writing and shall be deemed given and received upon personal
delivery, or seven (7) business days after deposit in the United States mail, by
certified or registered mail, postage prepaid and addressed as follows or, if by
facsimile transmission, on the same day as such facsimile transmission is
confirmed received at the applicable number enumerated below:
To the Purchasers: At their respective addresses and facsimile numbers
enumerated on the Schedule of Purchasers attached
hereto as Exhibit A or at such other address as
---------
Purchaser shall have furnished the Company in writing.
with a copy to: Blake, Xxxxxxx & Xxxxxxx
0xx Xxxxx, 00 Xxxxx'x Xxxxxx
Xxxxxx, Xxxxxxx XX0X0XX
Fax: 0000-000-0000
To the Company: BioMarin Pharmaceutical Inc.
000 Xxx Xxxxx Xxxx Xxxxxxxxx
Xxxxxx, XX 00000
Attn: Corporate Secretary
Fax: 000-000-0000
-14-
with a copy to: Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx, P.C.
000 Xxxx Xxxx Xxxx
Xxxx Xxxx, Xxxxxxxxxx 00000
Attn: Xxxxxxx X. Xxxxxx, Esq.
Fax: 000-000-0000
Either party may change by notice the address to which notices to it are to be
addressed.
(e) If any provision of this Agreement as applied to either party or
to any circumstances shall be adjudged by a court of competent jurisdiction to
be illegal, void, voidable or unenforceable, the same shall in no way affect the
other provisions of this Agreement which shall continue and remain in full force
and effect; provided that no such severability shall be effective if it
materially changes the economic benefit of this Agreement to any party.
(f) This Agreement has been entered into and shall be interpreted in
accordance with the internal laws of the State of California, applied to
contracts entered into in the State of California, without regard to conflict of
law provisions.
(g) This Agreement may be signed and delivered in counterparts, and
by facsimile, with the same effect as if the signatures thereto and hereto were
upon the same instrument and delivered in person.
-15-
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first written above.
"COMPANY"
BIOMARIN PHARMACEUTICAL INC.
a Delaware corporation
By: /s/ Xxxx X. Xxxxx
----------------------------------
Name: Xxxx X. Xxxxx
---------------------------------
Title: President and Secretary
--------------------------------
"PURCHASER"
By: __________________________________
Name: ________________________________
Title: _______________________________
-16-
EXHIBIT A
SCHEDULE OF PURCHASERS
Name and Address Principal Amount
----------------------------------------------------------------------------------
A&A Actienbank GmbH $7,000,000.00
----------------------------------------------------------------------------------
Glyko Biomedical Ltd. $4,300,000.00
----------------------------------------------------------------------------------
XxXxxx Asset Management SA $ 9,700,00.00
----------------------------------------------------------------------------------
Mr. Xxxxxx Xxxxxxxxxxx $5,000,000.00
----------------------------------------------------------------------------------
GRAND TOTAL: $ 26,000,000
----------------------------------------------------------------------------------
-17-
EXHIBIT B
[APPLICABLE REGULATION D OR REGULATION S LEGEND SPECIFIED IN NOTE PURCHASE
AGREEMENT]
CONVERTIBLE PROMISSORY NOTE
April 12, 1999
$_______________ Novato, California
FOR VALUE RECEIVED, BioMarin Pharmaceutical Inc. a Delaware corporation
(the "COMPANY") promises to pay to or to the order of ____________________
("HOLDER"), or its registered assigns, the principal sum of __________ dollars
($_________), or such lesser amount as shall equal the outstanding principal
amount hereof, together with interest from the date of this Note on the unpaid
principal balance at a rate equal to ten percent (10.00%) per annum, computed on
the basis of the actual number of days elapsed and a year of 365 days. All
unpaid principal, together with any then unpaid and accrued interest and other
amounts payable hereunder, shall be due and payable on the earliest of (i) April
12, 2002 (the "MATURITY DATE"), (ii) immediately prior to a sale of all or
substantially all of the assets of the Company or a merger or acquisition of the
Company with or into another entity in which the holders of the voting capital
stock of the Company immediately prior to such merger or acquisition hold less
than fifty percent (50%) of the voting capital stock of the successor entity
following such transaction, (iii) the effective date of the final prospectus
relating to an initial public offering of the Company's capital stock, which
securities are to be listed on a foreign or a United States exchange or
exchanges or the Nasdaq national market, with net proceeds to the Company (after
deducting underwriters' discounts and expenses) of at least $20 million, or (iv)
when, upon or after the occurrence of an Event of Default (as defined below),
such amounts are declared due and payable by Holder or made automatically due
and payable in accordance with the terms hereof. This Note is one of the "Notes"
issued pursuant to the Convertible Note Purchase Agreement of even date herewith
(the "NOTE PURCHASE AGREEMENT") between Company and the Purchasers (as defined
in the Convertible Note Purchase Agreement).
The following is a statement of the rights of Holder and the conditions to
which this Note is subject, and to which Holder, by the acceptance of this Note,
agrees:
1. DEFINITIONS. As used in this Note, the following capitalized terms
-----------
have the following meanings:
(a) "Financial Statements" shall mean, with respect to any accounting
period for the Company, statements of operations, retained earnings and cash
flow of the Company for such period, and balance sheets of the Company as of the
end of such period, setting forth in each case in comparative form figures for
the corresponding period in the preceding fiscal year if such period is less
than a full fiscal year or, if such period is a full fiscal year, corresponding
figures from the preceding fiscal year, all prepared in reasonable detail and in
accordance with GAAP.
(b) "GAAP" shall mean generally accepted accounting principles as in
effect in the United States of America from time to time.
(c) "Majority in Interest" shall mean, more than 50% of the aggregate
outstanding principal amount of the Notes issued pursuant to the Note Purchase
Agreement.
(d) "Obligations" shall mean and include all loans, advances, debts,
liabilities and obligations, howsoever arising, owed by the Company to the
Holder of every kind and description (whether or not evidenced by any note or
instrument and whether or not for the payment of money), now existing or
hereafter arising under or pursuant to the terms of this Note, the Note Purchase
Agreement and the other Transaction Documents, including, all interest, fees,
charges, expenses, attorneys' fees and costs and accountants' fees and costs
chargeable to and payable by the Company hereunder and thereunder, in each case,
whether direct or indirect, absolute or contingent, due or to become due, and
whether or not arising after the commencement of a proceeding under Title 11 of
the United States Code (11 U. S. C. Section 101 et seq.), as amended from time
-- ---
to time (including post-petition interest) and whether or not allowed or
allowable as a claim in any such proceeding.
(e) "Transaction Documents" shall mean this Note, each of the other
Notes issued under the Note Purchase Agreement and the Note Purchase Agreement
itself.
2. CERTAIN COVENANTS. While any amount of principal is outstanding under
-----------------
this Note:
(a) Information Rights: Notices. The Company shall furnish to Holder
the following:
(i) Quarterly Financial Statements. Within forty-five (45) days
------------------------------
after the last day of each of the Company's first three fiscal quarters of each
year, a copy of the Financial Statements of Company for such quarter and for the
fiscal year to date, certified by the chief financial officer or controller of
Company to present fairly the financial condition, results of operations and
other information presented therein and to have been prepared in accordance with
GAAP consistently applied, subject to normal year end adjustments and except
that no footnotes need be included with such Financial Statements, and
(ii) Annual Financial Statements. Within one hundred twenty (120)
---------------------------
days after the close of each fiscal year of Company, (i) copies of the audited
Financial Statements of Company for such year, audited by nationally recognized
independent certified public accountants, (ii) copies of the unqualified
opinions and management letters delivered by such accountants in connection with
such Financial Statements, and (iii) a report containing a description of
projected business prospects (including capital expenditures) and management's
discussion and analysis of financial condition and results of operation of
Company.
(b) Inspection Rights. Holder and its representatives shall have the
right, at any time during normal business hours, upon reasonable prior notice,
to visit and inspect the properties of Company and its corporate, financial and
operating records, and make abstracts therefrom, and to
-2-
discuss Company's affairs, finances and accounts with its directors, officers
and independent public accountants.
3. EVENTS OF DEFAULT. The occurrence of any of the following shall
-----------------
constitute an "Event of Default" under this Note and the other Transaction
Documents:
(a) Voluntary Bankruptcy or Insolvency Proceedings. The Company shall
(i) apply for or consent to the appointment of a receiver, trustee, liquidator
or custodian of itself or of all or a substantial part of its property, (ii) be
unable, or admit in writing its inability, to pay its debts generally as they
mature, (iii) make a general assignment for the benefit of its or any of its
creditors, (iv) be dissolved or liquidated, (v) become insolvent (as such term
may be defined or interpreted under any applicable statute), (vi) commence a
voluntary case or other proceeding seeking liquidation, reorganization or other
relief with respect to itself or its debts under any bankruptcy, insolvency or
other similar law now or hereafter in effect or consent to any such relief or to
the appointment of or taking possession of its property by any official in an
involuntary case or other proceeding commenced against it, or (vii) take any
action for the purpose of effecting any of the foregoing; or
(b) Involuntary Bankruptcy or Insolvency Proceedings. Proceedings for
the appointment of a receiver, trustee, liquidator or custodian of Company or of
all or a substantial part of its property, or an involuntary case or other
proceedings seeking liquidation, reorganization or other relief with respect to
the Company or its debts under any bankruptcy, insolvency or other similar law
now or hereafter in effect shall be commenced and an order for relief entered or
such proceeding shall not be dismissed or discharged within thirty (30) days of
commencement.
(c) Representations and Warranties Untrue. The representations and
warranties made by the Company in Section 6 of the Convertible Note Purchase
Agreement dated April 12, 1998 shall be found to have been, as of the Closing
Date (as defined therein), false, incorrect, incomplete or misleading in a
material respect when made.
4. RIGHTS OF HOLDER UPON DEFAULT. Upon the occurrence or existence of any
-----------------------------
Event of Default, immediately and without notice, all outstanding Obligations
payable to the Holder by the Company hereunder shall automatically become
immediately due and payable in cash pursuant to Section 13 hereof, without
presentment, demand, protest or any other notice of any kind, all of which are
hereby expressly waived, anything contained herein or in the other Transaction
Documents to the contrary notwithstanding. In addition to the foregoing
remedies, upon the occurrence or existence of any Event of Default, the Holder
may exercise any other right power or remedy granted to it by the Transaction
Documents or otherwise permitted to it by law, either by suit in equity or by
action at law, or both.
5. CONVERSION.
----------
(a) Voluntary Conversion. The Company has the right, at the Company's
option, on the Maturity Date, to convert the amounts owed to Holder under this
Note, in accordance with the provisions of Section 5(c) hereof, in whole or in
part, into fully paid and nonassessable shares of
-3-
Common Stock of Company. The number of shares of Common Stock into which this
Note may be converted shall be determined by dividing the aggregate principal
amount by the Conversion Price (as defined below) in effect at the time of such
conversion. The initial "Conversion Price" shall be equal to $10.00.
(b) Automatic Conversion. At any time prior to the Maturity Date, the
entire principal amount of this Note and any interest accrued thereon pursuant
to the terms hereof shall be automatically converted into shares of Common Stock
of the Company (at the Conversion Price then in effect) immediately prior to:
(i) any merger or acquisition of the Company with or into another entity in
which the holders of the voting capital stock of the Company immediately prior
to such merger or acquisition hold less than fifty percent (50%) of the voting
capital stock of the successor entity following such transaction, or (ii) a sale
of all or substantially all of the assets of Company, or (iii) the effective
date of the final prospectus relating to the initial public offering of the
Company's capital stock, which securities are to be listed on foreign or United
States exchange or exchanges or the Nasdaq national market, with net proceeds to
the Company (after deducting underwriters' discounts and expenses) of at least
$20,000,000.
(c) Conversion Procedure. If this Note is automatically converted
into Common Stock pursuant to this Section 5, written notice shall be delivered
to Holder at the address last shown on the records of Company for Holder or
given by Holder to Company for the purpose of notice or, if no such address
appears or is given, at the place where the principal executive office of
Company is located, notifying Holder of the conversion to be effected,
specifying the Conversion Price, the principal amount and any interest accrued
thereon pursuant hereto to be converted, the date on which such conversion is
expected to occur and calling upon such Holder to surrender to the Company, in
the manner and at the place designated, the Note. Upon such conversion of this
Note, the Holder shall surrender this Note, duly endorsed, at the principal
office of the Company. At its expense, the Company shall, as soon as practicable
thereafter, but in any event within ten (10) business days, issue and deliver to
such Holder at such principal office a certificate or certificates for the
number of shares of Common Stock to which the Holder shall be entitled upon such
conversion (bearing such legends as are required by the Note Purchase Agreement
and applicable state and Federal securities laws in the opinion of counsel to
Company), together with any other securities and property to which the Holder is
entitled upon such conversion under the terms of this Note, including a check
payable to the Holder for any cash amounts payable as described in Section 5(d).
The certificate or certificates representing the shares of Common Stock issuable
upon conversion of this Note shall be issued in the name of the Holder. Any
conversion of this Note pursuant to Section 5 shall be deemed to have been made
immediately prior to the closing of the issuance and sale of shares as described
in Section 5 and on and after such date Holder shall be treated for all purposes
as the record holder of such shares and a purchaser of such shares under the
Note Purchase Agreement and shall be bound by the terms of the Note Purchase
Agreement.
(d) Fractional Shares; Interest; Effect of Conversion. No fractional
shares shall be issued upon conversion of this Note. In lieu of the Company
issuing any fractional shares to the Holder upon the conversion of this Note,
the Company shall pay to the Holder an amount equal to the product obtained by
multiplying the Conversion Price by the fraction of a share of Common
-4-
Stock not issued pursuant to the previous sentence. In addition, the Company
shall pay to Holder any interest accrued on the amount to be paid by the Company
pursuant to the previous sentence. Upon conversion of this Note in full and the
payment of the amounts specified in this Section 5(d), the Company shall be
forever released from all its obligations and liabilities under this Note,
including but not limited to the covenants enumerated in Section 2.
6. CONVERSION PRICE ADJUSTMENTS.
----------------------------
(a) Adjustments for Stock Splits and Subdivisions. In the event the
---------------------------------------------
Company should at any time or from time to time after the date of issuance
hereof fix a record date for the effectuation of a split or subdivision of the
outstanding shares of Common Stock or the determination of holders of Common
Stock entitled to receive a dividend or other distribution payable in additional
shares of Common Stock or other securities or rights convertible into, or
entitling the holder thereof to receive directly or indirectly, additional
shares of Common Stock (hereinafter referred to as "COMMON STOCK EQUIVALENTS")
without payment of any consideration by such holder for the additional shares of
Common Stock or the Common Stock Equivalents, then, as of such record date (or
the date of such dividend distribution, split or subdivision if no record date
is fixed), the Conversion Price shall be appropriately decreased so that the
number of shares of Common Stock issuable upon conversion of this Note shall be
increased in proportion to such increase of outstanding shares.
(b) Adjustments for Reverse Stock Splits. If the number of shares of
------------------------------------
Common Stock outstanding at any time after the date hereof is decreased by a
combination of the outstanding shares of Common Stock, then, following the
record date of such combination, the Conversion Price shall be appropriately
increased so that the number of shares of Common Stock issuable on conversion
hereof shall be decreased in proportion to such decrease in outstanding shares.
(c) Redemption of Common Stock. Should any or all of the Company's
--------------------------
Common Stock be redeemed at any time prior to full payment of all amounts due
under this Note then this Note shall immediately become convertible into that
number of shares of the Company's Common Stock equal to the number of shares of
the Common Stock that would have been received if this Note had been converted
in full and the Conversion Price shall be immediately adjusted to equal the
quotient obtained by dividing (x) the aggregate Conversion Price of the maximum
number of shares of Common Stock into which this Note was convertible
immediately prior to such redemption, by (y) the number of shares of Common
Stock for which this Note is convertible immediately after such redemption.
(d) Adjustment for Dilutive Issuances. In addition to the adjustment
---------------------------------
of the respective Conversion Prices provided in Sections 6(a), 6(b) and 6(c)
above, the Conversion Price shall be subject to further adjustment from time to
time as follows:
(i) Special Definitions. For purposes of this Section 6(d), the
-------------------
following definitions shall apply:
-5-
(1) Options shall mean rights, options or warrants to
-------
subscribe for, purchase or otherwise acquire either Common Stock or Convertible
Securities.
(2) Original Issue Date shall mean the date of this Note.
-------------------
(3) Convertible Securities shall mean securities
----------------------
convertible into or exchangeable for Common Stock.
(4) Additional Shares of Common Stock shall mean all shares
---------------------------------
of Common Stock issued (or, pursuant to Section 6(d)(i)(6), deemed to be issued)
by the Company after the Original Issue Date other than shares of Common Stock
issued (or, pursuant to Section 6(d)(i)(6), deemed to be issued):
(a) to officers, directors and employees of, and
consultants to the Company pursuant to plans and arrangements approved by the
Board of Directors;
(b) by way of dividend or other distributions on
securities referred to in clause 6(a) above.
(c) in connection with an initial public offering of
the Company's capital stock, which securities are to be listed on a foreign or
United States exchange or exchanges.
(5) No Adjustment of Conversion Prices. No adjustment in
----------------------------------
the Conversion Price shall be made in respect of the issuance of Additional
Shares of Common Stock unless the consideration per share for an Additional
Share of Common Stock issued or deemed to be issued by the Company is less than
the Conversion Price on the date of, and immediately prior, to such issue.
(6) Deemed Issue of Additional Shares of Common Stock.
-------------------------------------------------
(a) Options and Convertible Securities. Except as
----------------------------------
otherwise provided in Sections 6(d)(i)(4)(a)-(c) and 6(d)(i)(5), in the event
the Company at any time or from time to time after the Original Issue Date shall
issue any Options or Convertible Securities or shall fix a record date for the
determination of any holders of any class of securities entitled to receive any
such Options or Convertible Securities, then the maximum number of shares (as
set forth in the instrument relating thereto without regard to any provisions
contained therein for a subsequent adjustment of such number) of Common Stock
issuable upon the exercise of such Options or, in the case of Convertible
Securities and Options therefor, the conversion or exchange of such Convertible
Securities, shall be deemed to be Additional Shares of Common Stock issued as of
the time of such issue or, in case such a record date shall have been fixed, as
of the close of business on such record date, provided that in any such case in
which additional shares of Common Stock are deemed to be issued:
-6-
(i) no further adjustment in the Conversion
Price shall be made upon the subsequent issue of Convertible Securities or
shares of Common Stock upon the exercise of such Options or conversion or
exchange of such Convertible Securities;
(ii) if such Options or Convertible Securities by
their terms provide, with the passage of time or otherwise, for any increase or
decrease in the consideration payable to the Company, or increase or decrease in
the number of shares of Common Stock issuable, upon the exercise, conversion or
exchange thereof, the Conversion Prices computed upon the original issue thereof
(or upon the occurrence of a record date with respect thereto), and any
subsequent adjustments based thereon, shall, upon any such increase or decrease
becoming effective, be recomputed to reflect such increase or decrease insofar
as it affects such Options or the rights of conversion or exchange under such
Convertible Securities;
(iii) upon the expiration of any such Options or
any rights of conversion or exchange under such Convertible Securities which
shall not have been exercised, the Conversion Prices computed upon the original
issue thereof (or upon the occurrence of a record date with respect thereto),
and any subsequent adjustments based thereon, shall, upon such expiration, be
recomputed as if:
(1) in the case of Convertible Securities or
Options for Common Stock, the only additional shares of Common Stock issued were
shares of Common Stock, if any, actually issued upon the exercise of such
Options or the conversion or exchange of such Convertible Securities, and the
consideration received therefor was the consideration actually received by the
Company for the issue of all such Options, whether or not exercised, plus the
consideration actually received by the Company upon such exercise, or for the
issue of all such Convertible Securities which were actually converted or
exchanged, plus the additional consideration, if any, actually received by the
Company upon such conversion or exchange, and
(2) in the case of Options for Convertible
Securities, only the Convertible Securities, if any, actually issued upon the
exercise thereof were issued at the time of issue of such Options and the
consideration received by the Company for the Additional Shares of Common Stock
deemed to have been then issued was the consideration actually received by the
Company for the issue of all such Options, whether or not exercised, plus the
consideration deemed to have been received by the Company upon the issue of the
Convertible Securities with respect to which such Options were actually
exercised;
(iv) no readjustment pursuant to clause (1) or
(2) above shall have the effect of increasing the Conversion Price to an amount
which exceeds the lower of (i) the Conversion Price on the original adjustment
date, or (ii) the Conversion Price that would have resulted from any issuance of
Additional Shares of Common Stock between the original adjustment date and such
readjustment date; and
-7-
v) in the case of any Options which expire by
their terms not more than thirty (30) days after the date of issue thereof, no
adjustment of the Conversion Price shall be made until the expiration or
exercise of all such Options.
(ii) Adjustment of Conversion Prices Upon Issuance of Additional
-----------------------------------------------------------
Shares of Common Stock. In the event the Company shall issue Additional Shares
----------------------
of Common Stock (including Additional Shares of Common Stock deemed to be issued
pursuant to Section 6(d)(i)(6)) without consideration or for a consideration per
share less than the Conversion Price in effect on the date of, and immediately
prior to such issue, then and in such event, such Conversion Price shall be
reduced, concurrently with such issue, to a price (calculated to the nearest
cent) determined by multiplying such Conversion Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such issue plus the number of shares of Common Stock which
the aggregate consideration received by the Company for the total number of
Additional Shares of Common Stock so issued would purchase at the Conversion
Price; and the denominator of which shall be the number of shares of Common
Stock outstanding immediately prior to such issue plus the number of such
Additional Shares of Common Stock so issued; and provided further that, for the
purposes of this Section 6(d)(ii), all shares of Common Stock issuable upon or
conversion of outstanding Convertible Securities shall be deemed to be
outstanding, and immediately after any Additional Shares of Common Stock are
deemed issued pursuant to Section 6(d)(i)(6), such Additional Shares of Common
Stock shall be deemed to be outstanding.
(iii) Determination of Consideration. For purposes of this
------------------------------
Section 6(d), the consideration received by the Company for the issue of any
Additional Shares of Common Stock shall be computed as follows:
(1) Cash and Property: Such consideration shall:
-----------------
(a) insofar as it consists of cash, be computed at the
aggregate amount of cash received by the Company prior to amounts paid or
payable for accrued interest or accrued dividends and prior to any commissions
or expenses paid by the Company;
(b) insofar as it consists of property other than
cash, be computed at the fair value thereof at the time of such issue, as
determined in good faith by the Board of Directors, except that any securities
so delivered shall be valued as provided herein; and
(c) in the event Additional Shares of Common Stock are
issued together with other shares or securities or other assets of the Company
for consideration which covers both, the consideration paid for the Additional
Shares of Common Stock be the proportion of the total of such consideration so
received, computed as provided above, as determined in good faith by the Board
of Directors.
(2) Options and Convertible Securities. The consideration
----------------------------------
per share received by the Company for Additional Shares of Common Stock deemed
to have been issued pursuant to Section 6(d)(i)(6), relating to Options and
Convertible Securities, shall be determined by dividing
-8-
(x) the total amount, if any, received or
receivable by the Company as consideration for the issue of such Options or
Convertible Securities, plus the minimum aggregate amount of additional
consideration (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such
consideration) payable to the Company upon the exercise of such Option or the
conversion or exchange of such Convertible Securities, or in the case of Options
for Convertible Securities, the exercise of such Options for Convertible
Securities and the conversion or exchange of such Convertible Securities, by
(y) the maximum number of shares of Common Stock
(as set forth in the instruments relating thereto, without regard to any
provision contained therein for a subsequent adjustment of such number) issuable
upon the exercise of such Options or the conversion or exchange of such
Convertible Securities.
(iv) No Impairment. The Company will not, by amendment of its
-------------
Certificate of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of
the terms to be observed or performed hereunder by the Company but will at all
times in good faith assist in the carrying out of all the provisions of this
Section 6 and in the taking of all such action as may be necessary or
appropriate in order to protect rights of the Holder hereunder against
impairment.
(v) Certificate as to Adjustments. Upon the occurrence of each
-----------------------------
adjustment or readjustment of the Conversion Price pursuant to this Section 6,
the Company at its expense shall promptly compute such adjustment or
readjustment in accordance with the terms hereof and furnish to the Holder a
certificate setting forth such adjustment or readjustment and showing in detail
the facts upon which such adjustment or readjustment is based. The Company
shall, upon the written request at any time of the Holder, furnish or cause to
be furnished to such Holder a like certificate setting forth (i) such
adjustments and readjustments, (ii) the Conversion Price at the time in effect,
and (iii) the number of shares of Common Stock and the amount, if any, of other
property which at the time would be received upon the conversion of the Note.
(e) Notices of Record Date, etc. In the event of:
---------------------------
(i) Any taking by the Company of a record of the holders of any
class of securities of the Company for the purpose of determining the holders
thereof who are entitled to receive any dividend (other than a cash dividend
payable out of earned surplus at the same rate as that of the last such cash
dividend theretofore paid) or other distribution or any right to subscribe for,
purchase or otherwise acquire any shares of stock of any class or any other
securities or property, or to receive any other right; or
(ii) Any capital reorganization of the Company, any
reclassification or recapitalization of the capital stock of Company or any
transfer of all or substantially all of the assets of Company to any other
person or entity or any consolidation or merger involving the Company; or
-9-
(iii) Any voluntary or involuntary dissolution, liquidation or
winding-up of the Company,
The Company will mail to Holder of this Note at least twenty (20) days
prior to the earliest date specified therein, a notice specifying (A) the date
on which any such record is to be taken for the purpose of such dividend,
distribution or right and the amount and character of such dividend,
distribution or right; and (B) the date on which any such reorganization,
reclassification, transfer, consolidation, merger, dissolution, liquidation or
winding-up is expected to become effective and the record date for determining
stockholders entitled to vote thereon.
(f) Reservation of Stock Issuable Upon Conversion. The Company shall
---------------------------------------------
at all times reserve and keep available out of its authorized but unissued
shares of Common Stock solely for the purpose of effecting the conversion of
this Note such number of its shares of Common Stock as shall from time to time
be sufficient to effect the conversion of this Note. If at any time the number
of authorized but unissued shares of Common Stock shall not be sufficient to
effect the conversion of the entire outstanding principal amount of this Note
and interest accrued thereon pursuant hereto, without limitation of such other
remedies as shall be available to the holder of this Note, the Company will use
its best efforts to take such corporate action as may, in the opinion of
counsel, be necessary to increase its authorized but unissued shares of Common
Stock to such number of shares as shall be sufficient for such purposes.
7. SUCCESSORS AND ASSIGNS. Subject to the restrictions on transfer
----------------------
described in Sections 9 and 10 below, the rights and obligations of the Company
and the Holder under this Note shall be binding upon and benefit the successors,
assigns, heirs, administrators and transferees of the parties.
8. WAIVER AND AMENDMENT. Any provision of this Note may be amended,
--------------------
waived or modified upon the written consent of the Company and holders of a
Majority in Interest of all then-outstanding Notes issued pursuant to the Note
Purchase Agreement.
9. TRANSFER OF THIS NOTE OR COMMON STOCK ISSUABLE ON CONVERSION HEREOF.
-------------------------------------------------------------------
With respect to any offer, sale or other disposition of this Note or the Common
Stock into which this Note may be converted, the Holder will give written notice
to the Company prior thereto, describing briefly the manner thereof, together
with a written opinion of Holder's counsel (if required by the Company), to the
effect that such offer, sale or other distribution may be effected without
registration or qualification (under any Federal or state law then in effect).
Upon receiving such written notice and reasonably satisfactory opinion, if so
requested, the Company, as promptly as practicable, shall notify Holder that
Holder may sell or otherwise dispose of this Note or such Common Stock, all in
accordance with the terms of the notice delivered to the Company. If a
determination has been made pursuant to this Section 9 that the opinion of
counsel for Holder is not reasonably satisfactory to the Company, the Company
shall so notify Holder promptly after such determination has been made. Each
Note thus transferred and each certificate representing the Common Stock thus
transferred shall bear a legend as to the applicable restrictions on
transferability in order to ensure compliance with the Securities Act of 1933,
as amended (the "ACT"), unless in the
-10-
opinion of counsel for the Company such legend is not required in order to
ensure compliance with the Act. The Company may issue stop transfer instructions
to its transfer agent in connection with such restrictions. Subject to the
foregoing, transfers of this Note shall be registered upon registration books
maintained for such purpose by or on behalf of the Company as provided in the
Note Purchase Agreement. Prior to presentation of this Note for registration of
transfer, the Company shall treat the registered holder hereof as the owner and
holder of this Note for the purpose of receiving all payments of principal and
interest hereon and for all other purposes whatsoever, whether or not this Note
shall be overdue and the Company shall not be affected by notice to the
contrary.
10. ASSIGNMENT BY COMPANY. Neither this Note nor any of the rights,
---------------------
interests or obligations hereunder may be assigned, by operation of law or
otherwise, in whole or in part, by the Company without the prior written consent
of the Holder except in connection with an assignment in whole to a successor
corporation to the Company, provided that such successor corporation acquires
all or substantially all of the Company's property and assets.
11. TAXES.
-----
(a) The Company shall pay or cause to be paid all present and future
taxes, duties, fees and other charges of whatsoever nature, if any, now or in
the future levied or imposed by the United States of America (or any state or
possession thereof) or an authority of the United States of America (or any
state or possession thereof) or any jurisdiction through or out of which a
payment is made on or in connection with the payment of any and all amounts due
under this Note.
(b) All payments of principal, interest and other amounts due under
this Note shall be made without deduction for or on account of any such taxes,
duties, fees or other charges.
(c) If the Company is prevented by operation of law or otherwise from
making or causing to be made such payments without deduction, the principal or
(as the case may be) interest or other amounts due under this Note shall be
increased to such amount as may be necessary so that the Purchaser receives the
full amount it would have received (taking into account any such taxes, duties,
fees or other charges payable on amounts payable by the Company under this
subsection) had such payments been made without such deduction.
(d) If subsection (c) above applies and the Purchaser so requires,
the Company shall deliver to the Purchaser official tax receipts evidencing
payment (or certified copies of them) within thirty (30) days of the date of
payment.
12. NOTICES. Any notice, request or other communication required or
-------
permitted hereunder shall be in writing and shall be deemed to have been duly
given if personally delivered or mailed by registered or certified mail, postage
prepaid, or by recognized overnight courier or personal delivery at the
respective addresses of the parties as set forth on Exhibit A of the Note
Purchase Agreement or on the register maintained by the Company three (3)
business days following such mailing or, if sent by facsimile transmission, on
the same date as such confirmed facsimile transmission was made. Any party
hereto may by notice so given change its address for future notice hereunder.
Notice shall conclusively be deemed to have been given when received.
-11-
13. PARI PASSU NOTES. Holder acknowledges and agrees that the payment of
----------------
all or any portion of the outstanding principal amount of this Note and all
interest hereon shall be pari passu in right of payment and in all other
respects to the other Notes issued pursuant to the Note Purchase Agreement or
pursuant to the terms of such Notes. In the event Holder receives payments in
excess of its pro rata share of the Company's payments to the holders of all of
the Notes, then such Holder shall hold in trust all such excess payments for the
benefit of the holders of the other Notes and shall pay such amounts held in
trust to such other holders upon demand by such holders.
14. PAYMENT. Payment by the Company of the principal amount under the Note
-------
and any interest accrued thereon pursuant hereto shall be made in lawful tender
of the United States.
15. DEFAULT RATE; USURY. In the event any interest is paid on this Note
-------------------
which is deemed to be in excess of the then legal maximum rate, then that
portion of the interest payment representing an amount in excess of the then
legal maximum rate shall be deemed a payment of principal and applied against
the principal of this Note.
16. EXPENSES; WAIVERS. If action is instituted to collect this Note, the
-----------------
Company promises to pay all costs and expenses, including, without limitation,
reasonable attorneys' fees and costs, incurred in connection with such action.
The Company hereby waives notice of default, presentment or demand for payment,
protest or notice of nonpayment or dishonor and all other notices or demands
relative to this instrument.
17. GOVERNING LAW. This Note and all actions arising out of or in
-------------
connection with this Note shall be governed by and construed in accordance with
the laws of the State of California, without regard to the conflicts of law
provisions of the State of California, or of any other state.
-12-
IN WITNESS WHEREOF, Company has caused this Note to be issued as of the
date first written above.
BIOMARIN PHARMACEUTICAL INC.
a Delaware corporation
By: /s/ Xxxx X. Xxxxx
----------------------------------
Name: Xxxx X. Xxxxx
--------------------------------
Title: President and Secretary
-------------------------------
-13-
EXHIBIT D
LEGAL OPINION OF COMPANY COUNSEL
-20-
April 12, 1999
Purchasers of Convertible Notes Pursuant
to Convertible Note Purchase Agreements dated
April 12, 1999, and XxXxxx Asset Management, S.A.
Pursuant to the Agency Agreement
dated April 12, 1999
Ladies and Gentlemen:
We have acted as counsel for BioMarin Pharmaceutical, Inc. (the
"Corporation") in connection with the negotiation of the Agency Agreement, dated
April 12, 1999, between the Corporation and XxXxxx Asset Management, S.A. (the
"Agency Agreement"), the Amended and Restated Registration Rights Agreement,
dated as of the date hereof (the "Amended Registration Rights Agreement"), the
Convertible Note Purchase Agreement (and all Schedules and Exhibits attached
thereto), dated as of the date hereof, between the Corporation and you (the
"Purchase Agreement"), the form of Convertible Promissory Note (the "Note") and
the purchase of the Notes by you pursuant to the terms of the Purchase
Agreement. As such counsel, we have made such legal and factual examinations as
we have deemed advisable or necessary for the purpose of rendering this opinion.
In addition, we have examined, among other things, originals or copies of such
corporate records of the Corporation and other such documents as we consider
necessary or advisable for the purposes of rendering this opinion. In such
examination we have assumed the genuineness of all signatures by parties thereto
on original documents, the conformity to original documents of all copies
submitted to us, the legal capacity of natural persons and the due execution and
delivery of all documents by parties thereto other than the Corporation where
due execution and delivery are a prerequisite to the effectiveness thereof. In
issuing this opinion we have also assumed that the par value of each share of
the Corporation's capital stock issued and outstanding has been paid in.
We are admitted to practice law only in the State of California and we
express no opinion herein concerning any laws other than the laws of the State
of California, the corporate law of the State of Delaware and the Federal laws
of the United States.
As used in this opinion, the expression "to our knowledge" with reference
to matters of fact means that, after an examination of documents made available
to us by the Corporation, and after inquiries of officers of the Corporation,
but without any further independent factual investigation, we find no reason to
believe that the opinions expressed herein are factually incorrect. Further,
the expression "to our knowledge" with reference to matters of fact refers to
the current actual knowledge of the attorneys of this firm who have worked on
matters for the Corporation solely in
Convertible Note Financing
April 12, 1999
Page 2
connection with the Agency Agreement, the Purchase Agreement and the Amended
Registration Rights Agreement, the Notes and the transactions contemplated
thereby. Except to the extent expressly set forth herein or as we otherwise
believe to be necessary to our opinion, we have not undertaken any independent
investigation to determine the existence or absence of any fact, and no
inference as to our knowledge of the existence or absence of any fact should be
drawn from our representation of the Company or the rendering of the opinion set
forth below.
For purposes of this opinion, we are assuming that you have all requisite
power and authority, and have taken any and all necessary partnership action, to
execute and deliver, as applicable, the Agency Agreement, the Purchase Agreement
and the Amended Registration Rights Agreement, and we are assuming that the
representations and warranties made by you, as applicable, contained in the
Agency Agreement and in the Purchase Agreement are true and correct. We are
also assuming that, as applicable, you have purchased the Notes for value, in
good faith and without notice of any adverse claims within the meaning of the
California Uniform Commercial Code.
The opinions hereinafter expressed are subject to the following
qualifications:
(a) We express no opinion as to the effect of applicable bankruptcy,
insolvency, reorganization, moratorium or other similar federal or state laws
affecting the rights of creditors generally;
(b) We express no opinion as to the effect or availability of rules
of law governing specific performance, injunctive relief or other equitable
remedies (regardless of whether any such remedy is considered in a proceeding at
law or in equity);
(c) We express no opinion as to compliance or noncompliance with
applicable Unites States Federal and state anti-fraud statutes and regulations
concerning the issuance of securities;
(d) We express no opinion as to the enforceability of the
indemnification provisions of the Amended Registration Rights Agreement to the
extent the provisions thereof may be subject to limitations of public policy and
the effect of applicable statutes and judicial decisions; and
Based upon and subject to the foregoing, and subject to the
qualifications contained herein, we are of the opinion that, except as set forth
in the Purchase Agreement:
1. The Corporation is validly existing and in good standing under and by
virtue of the laws of the State of Delaware and has the corporate power and
authority to create, issue and sell the
Convertible Note Financing
April 12, 1999
Page 3
Notes, to issue the shares of the Corporation's Common Stock issuable upon
conversion of the Notes, and to carry out its obligations under the Agency
Agreement, the Purchase Agreement, the Notes and the Amended Registration Rights
Agreement;
2. The authorized capital stock of the Corporation consists of 50,000,000
shares of Common Stock. Immediately prior to the Closing, 26,176,180 shares of
Common Stock are issued and outstanding, all of which have been duly authorized
and validly issued, are fully paid and nonassessable, and free of any pre-
emptive or similar rights contained in the Amended And Restated Certificate of
Incorporation or Bylaws of the Corporation or, to our knowledge, in any
agreement to which the Corporation is a party. The Corporation has reserved a
total of 2,600,000 shares of its Common Stock for issuance upon conversion of
the Notes. The shares of the Corporation's Common Stock issuable upon
conversion of the Notes, if issued as of the date hereof, and in accordance with
the terms of the Agency Agreement, the Purchase Agreement and the Notes, would
be duly authorized, validly issued, fully paid and nonassessable and free of any
liens, encumbrances or preemptive or similar rights contained in the Restated
Certificate or Bylaws of the Corporation, or to our knowledge, in any agreement
to which the Corporation is a party, other than those which may be created by
or imposed upon the holders thereof through no action of the Corporation.
Warrants to purchase 801,500 shares of Common Stock are currently outstanding.
Options to purchase a total of 3,406,254 shares of Common Stock had been granted
and are outstanding under the 1997 Stock Plan, as amended, and the 1998
Directors Plan. The Corporation has undertaken the obligation to issue up to
255,222 shares of its Common Stock to employees of Glyko, Inc. upon the exercise
of certain of their outstanding options to purchase capital stock of Glyko
Biomedical Ltd., which options were assumed by the Corporation in connection
with its acquisition of Glyko, Inc. in October 1998. Genzyme Corporation is
contractually obligated to purchase $10 million worth of the Corporation's
capital stock in a private placement to take place immediately prior to the
initial public offering of the Corporation's capital stock (subject to certain
qualifications) at the same price per share at which such securities are offered
and sold to the public in connection with the initial public offering. To the
best of our knowledge there are no other options, warrants, conversion
privileges, pre-emptive rights (other than those pursuant to: (i) the pre-
emptive rights agreement between Glyko Biomedical Ltd. and the Corporation dated
June 27, 1997, (ii) the pre-emptive rights agreement between the Corporation and
Genzyme Corporation dated September 4, 1998, and (iii) the pre-emptive rights
agreement between BB BioVentures L.P. and the Corporation dated December 30,
1997 ) or other rights presently outstanding to purchase or otherwise acquire
any capital stock or other securities of the Company;
3. The Agency Agreement, the Purchase Agreement, the Notes and the
Amended Registration Rights Agreement have each been duly authorized, executed
and delivered by the Corporation and are each a legal, valid and binding
obligation of the Corporation in accordance with their respective terms;
Convertible Note Financing
April 12, 1999
Page 4
4. All necessary corporate action has been taken by the Corporation, its
directors and its stockholders to authorize the creation, issue, offering and
sale of the Notes and, if such issuance were made today, to authorize and
reserve a sufficient number of shares of the Corporation's Common Stock for
issuance upon conversion of the Notes and the issuance of shares of Common Stock
upon issuance of the Notes;
5. The execution and delivery of the Agency Agreement, the Purchase
Agreement, the Notes, the Amended Registration Rights Agreement and the
completion of the transactions contemplated thereby, including the authorization
and reservation of a sufficient number of shares for future issuance upon the
conversion of the Notes, do not conflict with any provisions of the Amended and
Restated Certificate of Incorporation or Bylaws of the Corporation;
6. Assuming compliance by XxXxxx Asset Management, S.A. with the terms of
the Agency Agreement, and compliance with all applicable securities laws of any
jurisdiction within the United States by any holder of the Notes or the shares
of the Corporation's Common Stock issuable upon conversion of the Notes, except
for the filing of notices that may be required under United States Federal and
state securities laws with regard to (i) and (ii) below, no further filing,
consent, approval, authorization or qualification is required by the Corporation
in connection with: (i) the execution and delivery of the Agency Agreement, the
Subscription Agreement, the Amended Registration Rights Agreement or the Notes,
(ii) the valid authorization, issuance and sale of the Notes and the
authorization and reservation of a sufficient number of shares of the
Corporation's Common Stock for issuance upon conversion of the Notes, or, if
such shares were issued as of the date hereof, the issuance of such shares, to:
(a) persons who are not "U.S. persons," as defined in Regulation S promulgated
under the Securities Act, who are purchasing in "offshore transactions," as
defined in Regulation S, or (b) to U.S. persons who are "accredited investors"
as defined in Rule 501(a) of Regulation D promulgated under the Securities Act,
(iii) the resale of any the shares of the Corporation's Common Stock issuable
upon conversion of Notes which were issued in reliance on the exemption from
registration provided in Regulation S: (a) outside the United States, as defined
in Regulation S, to a person who is not a U.S. person, is not acquiring the
shares of the Corporation's Common Stock issuable upon conversion of the Notes
for the account or benefit of any U.S. person, who certifies to that effect, and
who agrees in writing to resell the shares of the Corporation's Common Stock
issuable upon conversion of the Notes only in accordance with the provisions of
Regulation S, pursuant to registration under the Securities Act or pursuant to
an available exemption from the registration requirements thereunder, or (b)
inside the United States, as defined in Regulation S, after the expiration of
one year from the date of issuance of the Notes, to a U.S. person who
acknowledges, in writing, that the shares of the Corporation's Common Stock
issuable upon conversion of the Notes are considered "restricted securities"
under Rule 144 promulgated under the Securities Act, and must be sold in
accordance therewith, and who agrees, in writing, to resell the securities only
in accordance with the provisions of Regulation S, pursuant to registration
under the Securities Act or pursuant to an available exemption from the
registration requirements thereunder,
Convertible Note Financing
April 12, 1999
Page 5
and (iv) the resale of any of the shares of the Corporation's Common Stock
issuable upon conversion of Notes which were issued in reliance on the exemption
from registration provided in Regulation D pursuant to registration under the
Securities Act (subject to the restrictions enumerated in Rule 144) or pursuant
to an available exemption from the registration requirements thereunder to a
purchaser who agrees to be bound by the restrictions contained in Rule 144.
This opinion is intended solely for your use and benefit and solely in
connection with the purchase of the Shares and is not to be relied upon by other
persons or entities or by you or any other person or entity for any other
purpose without our prior written consent.
Very truly yours,
XXXXXX XXXXXXX XXXXXXXX & XXXXXX
Professional Corporation
EXHIBIT E
SCHEDULE OF EXCEPTIONS
6. (f) As of April 12, 1999, BioMarin believes that it is in the final stages
of a negotiation to acquire certain assets and intellectual property rights
related to the research reagents business of Oxford GlycoSciences plc ("OGS"),
Abingdon, England. Based on current discussions, the purchase will require the
payment of $750,000 upon signing, $750,000 upon successful transfer of
technology, and a contingent amount of up to $600,000 based upon the sales
performance of the product lines acquired from OGS over the two year period
after signing. The contingent amount will be paid at the end of the two year
period.
-21-
EXHIBIT F
ACCREDITED INVESTOR QUESTIONNAIRE
The undersigned, as a purchaser of a Note convertible into shares of common
stock (the "Securities") of BIOMARIN PHARMACEUTICAL INC. (the "Company"), has
represented in its Convertible Note Purchase Agreement that it is an "accredited
investor" as defined in Rule 501 of Regulation D promulgated under the
Securities Act of 1933, as amended (the "Securities Act"). As part of such
representation, it has indicated below the categories enumerated in Rule 501(a)
which it satisfies.
The undersigned understands that the Company is relying on this information
in determining to sell the Securities to the undersigned in a manner exempt from
the registration requirements of the Securities Act and applicable state
securities laws.
ACCREDITED INVESTOR STATUS
The undersigned represents and warrants that it is [check each applicable
item]:
______ (i) A bank, as defined in Section 3(a)(2) of the Securities
Act, or a savings and loan association or other institution
as defined in Section 3(a)(5)(A) of the Securities Act.
whether acting in its individual or fiduciary capacity.
______ (ii) A broker or dealer registered pursuant to Section 15 of the
Securities Exchange Act of 1934, as amended.
______ (iii) An insurance company as defined In Section 2(13) of the
Securities Act.
______ (iv) An investment company registered under the Investment
Company Act of 1940 (the "1940 Act").
______ (v) A business development company (as defined in Section
2(a)(48) of the 1940 Act).
______ (vi) A private business development company (as defined in
Section 202(a)(22) of the Investment Advisers Act of 1940).
______ (vii) A Small Business Investment Company licensed by the Small
Business Administration under Section 301(c) or (d) of the
Small Business Investment Act of 1958.
______ (viii) An employee benefit plan within the meaning of the
Employee Retirement Income Security Act of 1974 ("ERISA"),
if the investment decision is made by a plan fiduciary as
defined in Section 3(21) of ERISA, which is either a bank,
savings and loan association, insurance company or
registered investment advisor, or if the employee benefit
plan has total assets in excess of $5,000,000, or, if a
self-directed plan, with investment decisions made solely
by persons that are accredited investors.
______ (ix) Any plan for the benefit of employees established and
maintained by the U.S. government, a state, its political
subdivisions, or any agency or instrumentality of the U.S.
government, a state or its political subdivisions, if such
plan has total assets in excess of $5,000,000.
______ (x) An organization described in Section 501(c)(3) of the
Internal Revenue Code, corporation, Massachusetts or
similar business trust, or partnership, not formed for the
specific purpose of acquiring the Securities offered,
having total assets in excess of $5,000,000.
______ (xi) A director, executive officer or general partner of the
issuer of the Securities, or any director, executive
officer, or general partner of a general partner of the
Company.
______ (xii) A natural person whose individual net worth, or joint net
worth with that person's spouse, at the time of his
purchase exceeds $1,000,000.
______ (xiii) A natural person who had an individual income in excess of
$200,000 in each of the two most recent years or a joint
income with that person's spouse in excess of $300,000 in
each of those years, and has a reasonable expectation of
reaching the same income level in the current year.
______ (xiv) A trust, with total assets in excess of $5,000,000, not
formed for the specific purpose of acquiring the
Securities offered hereby, whose purchase is directed by a
sophisticated person as described in Rule 506(b)(2)(ii) of
Regulation D under the Securities Act.
______ (xv) An entity in which all of the equity owners are accredited
investors.
______ (xvi) A self-directed XXX, Xxxxx, or similar plan of which the
individual directing the investments qualifies as an
"accredited investor" under one or more of items (a)-(o)
above. Also check the item(s) (a)-(o) above that applies.
As used in this questionnaire, the term "net worth" means the excess of
total assets over total liabilities. In computing net worth for the purpose of
this questionnaire, the principal residence of the investor must be valued at
cost, including cost of improvements, or at recently appraised value by an
institutional lender making a secured loan, net of encumbrances. In determining
income, an investor should add to adjusted gross income any amount attributable
to tax exempt income received, losses claimed as a limited partner in any
limited partnership, deductions claimed for depletion, contributions to an XXX
or Xxxxx retirement plan, alimony payments, and any amount by which income from
long-term capital gains has been reduced in arriving at adjusted gross income.
IN WITNESS WHEREOF, the undersigned has executed this Questionnaire as of
the ______day of April, 1999.
PURCHASER
By: ______________________________
Name _____________________________
Title ____________________________
Printed or Typed Name and Title of Person
Signing
